Galectin Therapeutics Inc.
NASDAQ Capital MarketTotal Valuation
Galectin Therapeutics Inc. carries a market capitalization of 225.89M, placing it among publicly traded companies globally. Its enterprise value stands at 434.38M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 225.89M |
| Enterprise Value | 434.38M |
Share Statistics
Galectin Therapeutics Inc. currently has 66.31M shares outstanding.
| Shares Outstanding | 66.31M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -2.21 |
| P/TBV Ratio | -2.21 |
| P/FCF Ratio | -19.07 |
| P/OCF Ratio | -19.07 |
Financial Position
Galectin Therapeutics Inc. maintains a current ratio of 0.10, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -100.66, indicating conservative leverage, while an interest coverage ratio of -2.01 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.10 |
| Quick Ratio | 0.09 |
| Debt / Equity | -100.66 |
| Debt / EBITDA | -8.85 |
| Interest Coverage | -2.01 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -183.01 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Galectin Therapeutics Inc.'s stock has declined approximately -32.61297% over the past 52 weeks. The 50-day moving average sits at 3.83, while the 200-day moving average is 3.21.
| Beta (5Y) | N/A |
| 52-Week Price Change | -32.61297% |
| 50-Day Moving Average | 3.83 |
| 200-Day Moving Average | 3.21 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -15.56M, while operating income came in at -15.62M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -15.62M |
| Pretax Income | -27.84M |
| Net Income | -27.84M |
| EBITDA | -15.56M |
| EBIT | -15.62M |
| Earnings Per Share (EPS) | -0.43 |
Balance Sheet
Galectin Therapeutics Inc. holds 13.27M in cash and equivalents against 137.76M in total debt, resulting in a net debt position of 124.43M. Total book value stands at -139.05M, with working capital of -136.96M providing operational flexibility.
| Cash & Cash Equivalents | 13.27M |
| Total Debt | 137.76M |
| Net Debt | 124.43M |
| Equity (Book Value) | -139.05M |
| Book Value Per Share | -2.10 |
| Working Capital | -136.96M |
Cash Flow
Galectin Therapeutics Inc. produced -15.89M in operating cash flow over the past twelve months.
| Operating Cash Flow | -15.89M |
| Capital Expenditures | N/A |
| Free Cash Flow | -15.89M |
| FCF Per Share | -0.24 |
Dividends & Yields
The company's payout ratio of 0.66 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 0.66 |
| Shareholder Yield | -5.00 |
| FCF Yield | -5.25 |
Stock Splits
Galectin Therapeutics Inc.'s most recent stock split took place on March 23, 2012 with a 6:1 split ratio.
| Last Split Date | 3/23/2012 |
| Split Ratio | 6:1 |
Scores
Galectin Therapeutics Inc. posts an Altman Z-Score of -55.54, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -55.54 |